Title | In Vivo |
Abbreviation | In Vivo |
Publication Type | Journal |
Subject Area, Categories, Scope | Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q2); Medicine (miscellaneous) (Q2); Cancer Research (Q3); Pharmacology (Q3) |
h-index | 74 |
Overall Rank/Ranking | 10353 |
SCImago Journal Rank (SJR) | 0.562 |
Impact Score | 1.81 |
Publisher | International Institute of Anticancer Research |
Country | Greece |
ISSN | 17917549, 0258851X |
Best Quartile | Q2 |
Coverage History | 1987-2025 |
In Vivo is a journal covering the technologies/fields/categories related to Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q2); Medicine (miscellaneous) (Q2); Cancer Research (Q3); Pharmacology (Q3). It is published by International Institute of Anticancer Research. The overall rank of In Vivo is 10353. According to SCImago Journal Rank (SJR), this journal is ranked 0.562. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 74. The best quartile for this journal is Q2.
The ISSN of In Vivo journal is 17917549, 0258851X. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. In Vivo is cited by a total of 2309 articles during the last 3 years (Preceding 2024).
The Impact IF 2024 of In Vivo is 1.81, which is computed in 2025 as per its definition. In Vivo IF is decreased by a factor of 0.07 and approximate percentage change is -3.72% when compared to preceding year 2023, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2024 of In Vivo is 1.81. If the same downward trend persists, Impact IF may fall in 2025 as well.
Year | Impact IF |
---|---|
2025/2026 | Coming Soon |
2024 | 1.81 |
2023 | 1.88 |
2022 | 2.33 |
2021 | 2.34 |
2020 | 2.11 |
2019 | 1.64 |
2018 | 1.68 |
2017 | 1.24 |
2016 | 1.10 |
2015 | 1.01 |
2014 | 1.12 |
In Vivo has an h-index of 74. It means 74 articles of this journal have more than 74 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of In Vivo is 17917549, 0258851X. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of In Vivo is 10353. According to SCImago Journal Rank (SJR), this journal is ranked 0.562. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
Year | SJR |
---|---|
2025/2026 | Coming Soon |
2024 | 0.562 |
2023 | 0.555 |
2022 | 0.540 |
2021 | 0.522 |
2020 | 0.545 |
2019 | 0.458 |
2018 | 0.419 |
2017 | 0.409 |
2016 | 0.382 |
2015 | 0.401 |
2014 | 0.406 |
Year | Ranking |
---|---|
2025/2026 | Coming Soon |
2024 | 10353 |
2023 | 9742 |
2022 | 9593 |
2021 | 9577 |
2020 | 9276 |
2019 | 10587 |
2018 | 10946 |
2017 | 10780 |
2016 | 11413 |
2015 | 10889 |
2014 | 10543 |
In Vivo is published by International Institute of Anticancer Research. It's publishing house is located in Greece. Coverage history of this journal is as following: 1987-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of In Vivo is In Vivo. This abbreviation ('In Vivo') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q2); Medicine (miscellaneous) (Q2); Cancer Research (Q3); Pharmacology (Q3), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
In Vivo latest impact IF is 1.81. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 2.34 (2021) and 1.01 (2015), respectively, in the last 11 years. Moreover, its average IS is 1.66 in the previous 11 years.
The In Vivo has an SJR (SCImago Journal Rank) of 0.562, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 0.562 in 2024 and the lowest being 0.382 in 2016. Furthermore, the average SJR of the In Vivo over the previous 11-year period stands at 1.66.
The latest h-index of the In Vivo is 74.
The In Vivo is published by the International Institute of Anticancer Research, with its country of publication being the Greece.
The In Vivo is currently ranked 10353 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 9276 in 2020 and its lowest position of 11413 in 2016.
The standard ISO4 abbreviation for the In Vivo is In Vivo.
In Vivo is classified as a journal that the International Institute of Anticancer Research publishes.
The In Vivo encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The In Vivo is assigned the following International Standard Serial Numbers (ISSN): 17917549, 0258851X.
The best quartile for the In Vivo is Q2 (2024).
The In Vivo coverage history can be summarized as follows: 1987-2025.
Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
---|---|---|---|---|---|
Journal of Field Archaeology | journal | 7683 | Maney Publishing | 48 | 1.85 |
Analysis in Theory and Applications | journal | 19346 | Springer Netherlands | 11 | 0.00 |
SPE Production and Operations Symposium, Proceedings | conference and proceedings | 15907 | 21 | 0.00 | |
Revue Francophone des Laboratoires (discontinued) | journal | 23244 | Elsevier Masson s.r.l. | 8 | 0.00 |
Journal of Competition Law and Economics | journal | 11978 | Oxford University Press | 34 | 0.94 |
Mathematical Modelling and Analysis | journal | 9616 | Vilnius Gediminas Technical University | 31 | 1.49 |
Discourse | journal | 7536 | Routledge | 70 | 2.75 |
Statistica | journal | 18529 | University of Bologna | 9 | 0.38 |
Genes and Nutrition | journal | 4763 | BioMed Central Ltd | 69 | 4.26 |
Proceedings of the Royal Society of Queensland | journal | 28017 | Royal Society of Queensland | 12 | 0.17 |
Year | Impact Score (IS) |
---|---|
2025/2026 | Coming Soon |
2024 | 1.81 |
2023 | 1.88 |
2022 | 2.33 |
2021 | 2.34 |
2020 | 2.11 |
2019 | 1.64 |
2018 | 1.68 |
2017 | 1.24 |
2016 | 1.10 |
2015 | 1.01 |
2014 | 1.12 |